Loading
Avanos Medical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BLACKFORD GARY, was filed 15 Aug 2025.
Insider Decl.
318
Thresholds
n/a
Buy Volume
€1M
13 ops. · all time
Sell Volume
€380,924
11 ops. · all time
Who traded when
BuySaleKerr Holbrook5 sales
Gary Blackford2 buys
Since the insiders bought
- -28.0%Entry US$19.91 · Close at T+365 US$14.33
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,855 of 26,280 companies
36.9
score / 100
Value39
Quality35
FCF yld3.7%
Earn yld-6.2%
EV/EBITDA·
ROE-9.2%
Gross mgn50%
Net mgn-10%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$24.99
Analyst consensus
Income statement
RevenueUS$701.2M
Gross profitUS$353.9M50% margin
EBITDA-US$19.5M-3% margin
Net income-US$72.9M-10.4% margin
Valuation
PER (forward)20.0x
P/Book1.5x
Beta1.57
Balance sheet & cash
Market capUS$1.2B
Total debtUS$129.1M
Free Cash FlowUS$43.1M
Debt / Equity18%
Profitability & ownership
ROE-9.2%
ROA1.0%
% insiders3.3%
% institutions93.1%
Last declaration on 28 July 2026
Declarations318 total
444,730 shares0Common StockSEC:0001606498-26-000110:1
96,121 shares0Common StockSEC:0001606498-26-000111:1
54,886 shares0Common StockSEC:0001606498-26-000112:1
40,000 shares@ US$25.000.085% mcap31.2% of flowCommon StockSEC:0001606498-26-000105:0
4,817 shares@ US$25.000.010% mcap100.0% of flowCommon StockSEC:0001606498-26-000107:0
54,640 shares@ US$25.000.12% mcap94.8% of flowCommon StockSEC:0001606498-26-000108:0
50,090 shares@ US$25.000.11% mcap99.2% of flowCommon StockSEC:0001606498-26-000109:0
322,194 shares@ US$25.000.69% mcap41.4% of flowCommon StockSEC:0001606498-26-000110:0
444,730 shares@ US$25.000.95% mcap57.1% of flowCommon StockSEC:0001606498-26-000110:2
135,596 shares@ US$25.000.29% mcap55.9% of flowCommon StockSEC:0001606498-26-000111:0
96,121 shares@ US$25.000.20% mcap39.6% of flowCommon StockSEC:0001606498-26-000111:2
55,741 shares@ US$25.000.12% mcap48.6% of flowCommon StockSEC:0001606498-26-000112:0
54,886 shares@ US$25.000.12% mcap47.8% of flowCommon StockSEC:0001606498-26-000112:2
79,590 shares@ US$25.000.17% mcap62.1% of flowCommon StockSEC:0001606498-26-000105:1
13,811 shares@ US$25.000.029% mcap100.0% of flowCommon StockSEC:0001606498-26-000106:0
4,264 shares@ US$24.640.0088% mcap3.6% of flowCommon StockSEC:0001606498-26-000058:0
4,228 shares@ US$24.640.0087% mcap1.7% of flowCommon StockSEC:0001606498-26-000059:0
21,194 shares@ US$14.530.025% mcap1.5% of flowCommon StockSEC:0001606498-26-000052:0
29,481 shares0Common StockSEC:0001606498-26-000040:0
15,886 shares0Common StockSEC:0001606498-26-000042:0
101,341 shares0Common StockSEC:0001606498-26-000033:0
101,341 shares0Common StockSEC:0001606498-26-000038:0
15,886 shares0Common StockSEC:0001606498-26-000035:0
29,481 shares0Common StockSEC:0001606498-26-000031:0
15,886 shares0Common StockSEC:0001606498-26-000023:0
25 of 318 declarations
About Avanos Medical, Inc.
Gary Blackford (Director) made the two largest purchases at Avanos Medical, Inc.: EUR 375,654 and EUR 187,400 on August 13, 2025. Joseph Fralin Woody (Chief Executive Officer) bought EUR 134,284 on November 28, 2018, within a window from November 19 to November 28, 2018 in which three filers bought EUR 253,070. In all, 13 purchases worth EUR 1,349,894 (median EUR 77,188) against 11 sales worth EUR 380,924 (median EUR 12,461), so purchases are 54% of market trades.
The sales are small. Kerr Holbrook (SVP, Chief Commercial Officer) sold EUR 131,291 on November 18, 2025 and EUR 98,915 on March 6, 2025; Michael Greiner, then in charge of finance, sold EUR 66,286 on March 14, 2024.
Read moreShow less
This US healthcare and pharma company, valued at USD 1.2 billion and 3.3% held by its insiders, has 318 filings published from January 6, 2016 to July 28, 2026, including 271 grants. Michael Greiner (Former Interim CEO) signed the most, 31. Yearly volume rises from 20 in 2016 to 47 in 2025. The last twelve months hold 42 filings, 4 of them sales.
